+ 0 1 0 1 O
HCV 1 4 1 4 B-chronic_disease
RNA 5 8 5 8 O

+ 0 1 9 10 B-treatment
hepatitis 1 10 10 19 I-treatment
C 11 12 20 21 I-treatment
virus 13 18 22 27 I-treatment
( 19 20 28 29 I-treatment
HCV 20 23 29 32 I-treatment
) 23 24 32 33 I-treatment
antibody 25 33 34 42 I-treatment
( 34 35 43 44 O
confirmed 35 44 44 53 O
) 44 45 53 54 O

1 0 1 55 56 B-lower_bound
prior 2 7 57 62 O
line 8 12 63 67 O
of 13 15 68 70 O
systemic 16 24 71 79 B-treatment
therapy 25 32 80 87 I-treatment
for 33 36 88 91 O
multiple 37 45 92 100 B-cancer
myeloma 46 53 101 108 I-cancer
, 53 54 108 109 O
where 55 60 110 115 O
a 61 62 116 117 O
line 63 67 118 122 O
of 68 70 123 125 O
therapy 71 78 126 133 O
for 79 82 134 137 O
myeloma 83 90 138 145 O
is 91 93 146 148 O
defined 94 101 149 156 O
as 102 104 157 159 O
1 105 106 160 161 O
or 107 109 162 164 O
more 110 114 165 169 O
planned 115 122 170 177 O
cycles 123 129 178 184 O
of 130 132 185 187 O
single 133 139 188 194 B-treatment
agent 140 145 195 200 I-treatment
or 146 148 201 203 O
combination 149 160 204 215 B-treatment
therapy 161 168 216 223 I-treatment
, 168 169 223 224 O
as 170 172 225 227 O
well 173 177 228 232 O
as 178 180 233 235 O
a 181 182 236 237 O
planned 183 190 238 245 O
series 191 197 246 252 O
of 198 200 253 255 O
treatment 201 210 256 265 B-treatment
regimens 211 219 266 274 I-treatment
administered 220 232 275 287 O
in 233 235 288 290 O
a 236 237 291 292 O
sequential 238 248 293 303 O
manner 249 255 304 310 O
( 256 257 311 312 O
e.g. 257 261 312 316 O
lenalidomide 262 274 317 329 B-treatment
, 274 275 329 330 O
bortezomib 276 286 331 341 B-treatment
and 287 290 342 345 O
dexamethasone 291 304 346 359 B-treatment
induction 305 314 360 369 I-treatment
therapy 315 322 370 377 I-treatment
for 323 326 378 381 O
4 327 328 382 383 O
cycles 329 335 384 390 O
followed 336 344 391 399 O
by 345 347 400 402 O
autologous 348 358 403 413 B-treatment
stem 359 363 414 418 I-treatment
cell 364 368 419 423 I-treatment
transplantation 369 384 424 439 I-treatment
and 385 388 440 443 O
then 389 393 444 448 O
lenalidomide 394 406 449 461 B-treatment
maintenance 407 418 462 473 I-treatment
therapy 419 426 474 481 I-treatment
would 427 432 482 487 O
be 433 435 488 490 O
considered 436 446 491 501 O
1 447 448 502 503 O
line 449 453 504 508 O
of 454 456 509 511 O
prior 457 462 512 517 B-treatment
therapy 463 470 518 525 I-treatment
) 470 471 525 526 O

= 0 1 527 528 O
< 1 2 528 529 O
grade 3 8 530 535 B-upper_bound
2 9 10 536 537 I-upper_bound
peripheral 11 21 538 548 B-chronic_disease
neuropathy 22 32 549 559 I-chronic_disease

A 0 1 560 561 O
female 2 8 562 568 B-gender
of 9 11 569 571 O
childbearing 12 24 572 584 O
potential 25 34 585 594 O
is 35 37 595 597 O
a 38 39 598 599 O
sexually 40 48 600 608 O
mature 49 55 609 615 O
female 56 62 616 622 O
who 63 66 623 626 O

A 0 1 627 628 O
patient 2 9 629 636 O
who 10 13 637 640 O
receives 14 22 641 649 O
induction 23 32 650 659 B-treatment
therapy 33 40 660 667 I-treatment
with 41 45 668 672 I-treatment
lenalidomide 46 58 673 685 I-treatment
, 58 59 685 686 O
bortezomib 60 70 687 697 B-treatment
and 71 74 698 701 O
dexamethasone 75 88 702 715 B-treatment
and 89 92 716 719 O
achieves 93 101 720 728 O
a 102 103 729 730 O
PR 104 106 731 733 O
or 107 109 734 736 O
better 110 116 737 743 O
but 117 120 744 747 O
subsequently 121 133 748 760 O
progresses 134 144 761 771 O
on 145 147 772 774 O
continued 148 157 775 784 O
lenalidomide 158 170 785 797 O
or 171 173 798 800 O
lenalidomide 174 186 801 813 B-treatment
- 186 187 813 814 I-treatment
dexamethasone 187 200 814 827 I-treatment
would 201 206 828 833 O
be 207 209 834 836 O
eligible 210 218 837 845 O
provided 219 227 846 854 O
the 228 231 855 858 O
progression 232 243 859 870 O
occurs 244 250 871 877 O
60 251 253 878 880 B-lower_bound
days 254 258 881 885 I-lower_bound
or 259 261 886 888 O
more 262 266 889 893 O
after 267 272 894 899 O
discontinuation 273 288 900 915 O
of 289 291 916 918 O
the 292 295 919 922 O
bortezomib 296 306 923 933 O
; 306 307 933 934 O
similarly 308 317 935 944 O
, 317 318 944 945 O
ixazomib 319 327 946 954 B-treatment
exposure 328 336 955 963 O
is 337 339 964 966 O
allowed 340 347 967 974 O
provided 348 356 975 983 O
they 357 361 984 988 O
meet 362 366 989 993 O
the 367 370 994 997 O
definition 371 381 998 1008 O
of 382 384 1009 1011 O
proteasome 385 395 1012 1022 O
inhibitor 396 405 1023 1032 O
sensitive 406 415 1033 1042 O
disease 416 423 1043 1050 O

AST 0 3 1051 1054 B-clinical_variable
and 4 7 1055 1058 O
ALT 8 11 1059 1062 B-clinical_variable
< 12 13 1063 1064 O
2.5 14 17 1065 1068 B-upper_bound
x 18 19 1069 1070 I-upper_bound
upper 20 25 1071 1076 I-upper_bound
limits 26 32 1077 1083 I-upper_bound
of 33 35 1084 1086 I-upper_bound
normal 36 42 1087 1093 I-upper_bound
( 43 44 1094 1095 I-upper_bound
ULN 44 47 1095 1098 I-upper_bound
) 47 48 1098 1099 I-upper_bound

Absolute 0 8 1100 1108 B-clinical_variable
neutrophil 9 19 1109 1119 I-clinical_variable
count 20 25 1120 1125 I-clinical_variable
( 26 27 1126 1127 I-clinical_variable
ANC 27 30 1127 1130 I-clinical_variable
) 30 31 1130 1131 I-clinical_variable
> 32 33 1132 1133 O
= 33 34 1133 1134 O
1.0 35 38 1135 1138 B-lower_bound
x 39 40 1139 1140 I-lower_bound
10 41 43 1141 1143 I-lower_bound
^ 43 44 1143 1144 I-lower_bound
9 44 45 1144 1145 I-lower_bound
/ 45 46 1145 1146 I-lower_bound
L 46 47 1146 1147 I-lower_bound

Adequate 0 8 1148 1156 O
cardiac 9 16 1157 1164 B-chronic_disease
function 17 25 1165 1173 I-chronic_disease

All 0 3 1174 1177 O
participants 4 16 1178 1190 O
must 17 21 1191 1195 O
be 22 24 1196 1198 O
counseled 25 34 1199 1208 O
at 35 37 1209 1211 O
a 38 39 1212 1213 O
minimum 40 47 1214 1221 O
of 48 50 1222 1224 O
every 51 56 1225 1230 O
28 57 59 1231 1233 B-lower_bound
days 60 64 1234 1238 I-lower_bound
about 65 70 1239 1244 O
pregnancy 71 80 1245 1254 B-pregnancy
precautions 81 92 1255 1266 O
and 93 96 1267 1270 O
risks 97 102 1271 1276 O
of 103 105 1277 1279 O
fetal 106 111 1280 1285 O
exposure 112 120 1286 1294 O

Allogeneic 0 10 1295 1305 B-treatment
stem 11 15 1306 1310 I-treatment
cell 16 20 1311 1315 I-treatment
transplantation 21 36 1316 1331 I-treatment
is 37 39 1332 1334 O
allowed 40 47 1335 1342 O
provided 48 56 1343 1351 O
the 57 60 1352 1355 O
patient 61 68 1356 1363 O
is 69 71 1364 1366 O
> 72 73 1367 1368 O
= 73 74 1368 1369 O
1 75 76 1370 1371 B-lower_bound
year 77 81 1372 1376 I-lower_bound
from 82 86 1377 1381 O
transplant 87 97 1382 1392 O
at 98 100 1393 1395 O
time 101 105 1396 1400 O
of 106 108 1401 1403 O
registration 109 121 1404 1416 O
, 121 122 1416 1417 O
is 123 125 1418 1420 O
not 126 129 1421 1424 O
on 130 132 1425 1427 O
immunosuppressive 133 150 1428 1445 B-treatment
therapy 151 158 1446 1453 I-treatment
to 159 161 1454 1456 O
treat 162 167 1457 1462 O
/ 167 168 1462 1463 O
prevent 168 175 1463 1470 O
graft 176 181 1471 1476 B-chronic_disease
- 181 182 1476 1477 I-chronic_disease
versus 182 188 1477 1483 I-chronic_disease
- 188 189 1483 1484 I-chronic_disease
host 189 193 1484 1488 I-chronic_disease
disease 194 201 1489 1496 I-chronic_disease

Baseline 0 8 1497 1505 O
marrow 9 15 1506 1512 O
burden 16 22 1513 1519 O
of 23 25 1520 1522 O
myeloma 26 33 1523 1530 B-cancer
of 34 36 1531 1533 O
at 37 39 1534 1536 O
least 40 45 1537 1542 O
30 46 48 1543 1545 B-lower_bound
% 48 49 1545 1546 I-lower_bound

Calc 0 4 1547 1551 O
. 4 5 1551 1552 O
creatinine 6 16 1553 1563 B-clinical_variable
clearance 17 26 1564 1573 I-clinical_variable
> 27 28 1574 1575 O
= 28 29 1575 1576 O
30 30 32 1577 1579 B-lower_bound
mL 33 35 1580 1582 I-lower_bound
/ 35 36 1582 1583 I-lower_bound
min 36 39 1583 1586 I-lower_bound

Calculated 0 10 1587 1597 O
( 11 12 1598 1599 O
Calc 12 16 1599 1603 O
. 16 17 1603 1604 O
) 17 18 1604 1605 O
creatinine 19 29 1606 1616 B-clinical_variable
clearance 30 39 1617 1626 I-clinical_variable
> 40 41 1627 1628 O
= 41 42 1628 1629 O
30 43 45 1630 1632 B-lower_bound
mL 46 48 1633 1635 I-lower_bound
/ 48 49 1635 1636 I-lower_bound
min 49 52 1636 1639 I-lower_bound

Calculated 0 10 1640 1650 O
utilizing 11 20 1651 1660 O
the 21 24 1661 1664 O
Cockcroft 25 34 1665 1674 B-clinical_variable
- 34 35 1674 1675 I-clinical_variable
Gault 35 40 1675 1680 I-clinical_variable
formula 41 48 1681 1688 I-clinical_variable
or 49 51 1689 1691 O
24 52 54 1692 1694 O
- 54 55 1694 1695 O
hour 55 59 1695 1699 O
urine 60 65 1700 1705 O
collection 66 76 1706 1716 O

Cluster 0 7 1717 1724 B-clinical_variable
of 8 10 1725 1727 I-clinical_variable
differentiation 11 26 1728 1743 I-clinical_variable
( 27 28 1744 1745 I-clinical_variable
CD)4 28 32 1745 1749 I-clinical_variable
+ 32 33 1749 1750 I-clinical_variable
cells 34 39 1751 1756 I-clinical_variable
nadirs 40 46 1757 1763 I-clinical_variable
> 47 48 1764 1765 O
350 49 52 1766 1769 B-lower_bound
/ 52 53 1769 1770 I-lower_bound
mm^3 53 57 1770 1774 I-lower_bound
within 58 64 1775 1781 O
28 65 67 1782 1784 B-upper_bound
days 68 72 1785 1789 I-upper_bound
prior 73 78 1790 1795 I-upper_bound
to 79 81 1796 1798 O
registration 82 94 1799 1811 O

ECOG 0 4 1812 1816 B-clinical_variable
performance 5 16 1817 1828 I-clinical_variable
status 17 23 1829 1835 I-clinical_variable
0 24 25 1836 1837 B-lower_bound
- 25 26 1837 1838 O
2 26 27 1838 1839 B-upper_bound

Eastern 0 7 1840 1847 B-clinical_variable
Cooperative 8 19 1848 1859 I-clinical_variable
Oncology 20 28 1860 1868 I-clinical_variable
Group 29 34 1869 1874 I-clinical_variable
( 35 36 1875 1876 I-clinical_variable
ECOG 36 40 1876 1880 I-clinical_variable
) 40 41 1880 1881 I-clinical_variable
performance 42 53 1882 1893 I-clinical_variable
status 54 60 1894 1900 I-clinical_variable
0 61 62 1901 1902 B-lower_bound
- 62 63 1902 1903 O
2 63 64 1903 1904 B-upper_bound

G 0 1 1905 1906 B-treatment
- 1 2 1906 1907 I-treatment
CSF 2 5 1907 1910 I-treatment
and 6 9 1911 1914 O
platelet 10 18 1915 1923 B-treatment
transfusions 19 31 1924 1936 I-treatment
can 32 35 1937 1940 O
not 35 38 1940 1943 O
be 39 41 1944 1946 O
used 42 46 1947 1951 O
to 47 49 1952 1954 O
increase 50 58 1955 1963 O
counts 59 65 1964 1970 O
to 66 68 1971 1973 O
meet 69 73 1974 1978 O
eligibility 74 85 1979 1990 O
criteria 86 94 1991 1999 O

HIV+ 0 4 2000 2004 B-chronic_disease
patients 5 13 2005 2013 O
who 14 17 2014 2017 O
enroll 18 24 2018 2024 O
on 25 27 2025 2027 O
this 28 32 2028 2032 O
study 33 38 2033 2038 O
and 39 42 2039 2042 O
are 43 46 2043 2046 O
assigned 47 55 2047 2055 O
to 56 58 2056 2058 O
treatment 59 68 2059 2068 B-treatment
with 69 73 2069 2073 I-treatment
ixazomib 74 82 2074 2082 I-treatment
may 83 86 2083 2086 O
need 87 91 2087 2091 O
to 92 94 2092 2094 O
modify 95 101 2095 2101 O
their 102 107 2102 2107 O
anti 108 112 2108 2112 B-treatment
- 112 113 2112 2113 I-treatment
retroviral 113 123 2113 2123 I-treatment
therapy 124 131 2124 2131 I-treatment
prior 132 137 2132 2137 O
to 138 140 2138 2140 O
receiving 141 150 2141 2150 O
protocol 151 159 2151 2159 O
therapy 160 167 2160 2167 O
if 168 170 2168 2170 O
they 171 175 2171 2175 O
are 176 179 2176 2179 O
on 180 182 2180 2182 O
strong 183 189 2183 2189 B-treatment
inducers 190 198 2190 2198 I-treatment
or 199 201 2199 2201 I-treatment
potent 202 208 2202 2208 I-treatment
inhibitors 209 219 2209 2219 I-treatment
of 220 222 2220 2222 I-treatment
cytochrome 223 233 2223 2233 I-treatment
P450 234 238 2234 2238 I-treatment
3A4 239 242 2239 2242 I-treatment

Histologically 0 14 2243 2257 O
confirmed 15 24 2258 2267 O
diagnosis 25 34 2268 2277 O
of 35 37 2278 2280 O
symptomatic 38 49 2281 2292 B-cancer
multiple 50 58 2293 2301 I-cancer
myeloma 59 66 2302 2309 I-cancer

Involved 0 8 2310 2318 O
serum 9 14 2319 2324 B-clinical_variable
free 15 19 2325 2329 I-clinical_variable
light 20 25 2330 2335 I-clinical_variable
chain 26 31 2336 2341 I-clinical_variable
level 32 37 2342 2347 I-clinical_variable
> 38 39 2348 2349 O
= 39 40 2349 2350 O
10 41 43 2351 2353 B-lower_bound
mg 44 46 2354 2356 I-lower_bound
/ 46 47 2356 2357 I-lower_bound
dL 47 49 2357 2359 I-lower_bound
AND 50 53 2360 2363 O
an 54 56 2364 2366 O
abnormal 57 65 2367 2375 O
serum 66 71 2376 2381 B-clinical_variable
free 72 76 2382 2386 I-clinical_variable
light 77 82 2387 2392 I-clinical_variable
chain 83 88 2393 2398 I-clinical_variable
ratio 89 94 2399 2404 I-clinical_variable

Ixazomib 0 8 2405 2413 B-treatment
is 9 11 2414 2416 O
a 12 13 2417 2418 O
substrate 14 23 2419 2428 B-treatment
of 24 26 2429 2431 I-treatment
CYP3A4 27 33 2432 2438 I-treatment
and 34 37 2439 2442 O
CYP1A2 38 44 2443 2449 B-treatment

Known 0 5 2450 2455 O
active 6 12 2456 2462 O
hepatitis 13 22 2463 2472 B-chronic_disease
C 23 24 2473 2474 I-chronic_disease
based 25 30 2475 2480 O
on 31 33 2481 2483 O

Known 0 5 2484 2489 O
hepatitis 6 15 2490 2499 B-chronic_disease
B 16 17 2500 2501 I-chronic_disease
surface 18 25 2502 2509 O
antigen 26 33 2510 2517 O
positivity 34 44 2518 2528 O

Lenalidomide 0 12 2529 2541 B-treatment
- 12 13 2541 2542 O
refractory 13 23 2542 2552 B-cancer
disease 24 31 2553 2560 I-cancer
is 32 34 2561 2563 O
defined 35 42 2564 2571 O
as 43 45 2572 2574 O
disease 46 53 2575 2582 O
progression 54 65 2583 2594 O
on 66 68 2595 2597 O
or 69 71 2598 2600 O
progression 72 83 2601 2612 O
within 84 90 2613 2619 O
60 91 93 2620 2622 B-upper_bound
days 94 98 2623 2627 I-upper_bound
of 99 101 2628 2630 O
the 102 105 2631 2634 O
last 106 110 2635 2639 O
dose 111 115 2640 2644 O
of 116 118 2645 2647 O
a 119 120 2648 2649 O
lenalidomide 121 133 2650 2662 B-treatment
- 133 134 2662 2663 I-treatment
based 134 139 2663 2668 I-treatment
treatment 140 149 2669 2678 I-treatment

Light 0 5 2679 2684 B-chronic_disease
- 5 6 2684 2685 I-chronic_disease
chain 6 11 2685 2690 I-chronic_disease
( 12 13 2691 2692 I-chronic_disease
AL 13 15 2692 2694 I-chronic_disease
) 15 16 2694 2695 I-chronic_disease
amyloidosis 17 28 2696 2707 I-chronic_disease
or 29 31 2708 2710 O
polyneuropathy 32 46 2711 2725 B-chronic_disease
, 46 47 2725 2726 O
organomegaly 48 60 2727 2739 B-chronic_disease
, 60 61 2739 2740 O
endocrinopathy 62 76 2741 2755 B-chronic_disease
, 76 77 2755 2756 O
monoclonal 78 88 2757 2767 B-chronic_disease
gammopathy 89 99 2768 2778 I-chronic_disease
, 99 100 2778 2779 O
and 101 104 2780 2783 O
skin 105 109 2784 2788 B-chronic_disease
changes 110 117 2789 2796 I-chronic_disease
( 118 119 2797 2798 I-chronic_disease
POEMS 119 124 2798 2803 I-chronic_disease
) 124 125 2803 2804 I-chronic_disease
syndrome 126 134 2805 2813 I-chronic_disease

Liver 0 5 2814 2819 B-chronic_disease
disease 6 13 2820 2827 I-chronic_disease
with 14 18 2828 2832 O
history 19 26 2833 2840 O
of 27 29 2841 2843 O
positive 30 38 2844 2852 O
serology 39 47 2853 2861 O

Marrow 0 6 2862 2868 O
burden 7 13 2869 2875 O
of 14 16 2876 2878 O
myeloma 17 24 2879 2886 B-cancer
of 25 27 2887 2889 O
at 28 30 2890 2892 O
least 31 36 2893 2898 O
30 37 39 2899 2901 B-lower_bound
% 39 40 2901 2902 I-lower_bound

Men 0 3 2903 2906 B-gender
must 4 8 2907 2911 O
practice 9 17 2912 2920 B-contraception_consent
complete 18 26 2921 2929 I-contraception_consent
abstinence 27 37 2930 2940 I-contraception_consent
or 38 40 2941 2943 O
agree 41 46 2944 2949 B-contraception_consent
to 47 49 2950 2952 I-contraception_consent
use 50 53 2953 2956 I-contraception_consent
a 54 55 2957 2958 I-contraception_consent
condom 56 62 2959 2965 I-contraception_consent
during 63 69 2966 2972 O
sexual 70 76 2973 2979 O
contact 77 84 2980 2987 O
with 85 89 2988 2992 O
a 90 91 2993 2994 O
female 92 98 2995 3001 B-gender
of 99 101 3002 3004 O
childbearing 102 114 3005 3017 O
potential 115 124 3018 3027 O
, 124 125 3027 3028 O
even 126 130 3029 3033 O
if 131 133 3034 3036 O
they 134 138 3037 3041 O
have 139 143 3042 3046 O
had 144 147 3047 3050 O
a 148 149 3051 3052 O
successful 150 160 3053 3063 O
vasectomy 161 170 3064 3073 B-contraception_consent

Must 0 4 3074 3078 O
agree 5 10 3079 3084 O
to 11 13 3085 3087 O
not 14 17 3088 3091 B-pregnancy
become 18 24 3092 3098 I-pregnancy
pregnant 25 33 3099 3107 I-pregnancy
or 34 36 3108 3110 O
breast 37 43 3111 3117 O
feed 44 48 3118 3122 O
a 49 50 3123 3124 O
child 51 56 3125 3130 O
during 57 63 3131 3137 O
treatment 64 73 3138 3147 B-treatment
on 74 76 3148 3150 O
this 77 81 3151 3155 O
protocol 82 90 3156 3164 O

Must 0 4 3165 3169 O
agree 5 10 3170 3175 O
to 11 13 3176 3178 O
ongoing 14 21 3179 3186 O
pregnancy 22 31 3187 3196 B-pregnancy
testing 32 39 3197 3204 O

Must 0 4 3205 3209 O
either 5 11 3210 3216 O
commit 12 18 3217 3223 B-contraception_consent
to 19 21 3224 3226 I-contraception_consent
complete 22 30 3227 3235 I-contraception_consent
abstinence 31 41 3236 3246 I-contraception_consent
from 42 46 3247 3251 I-contraception_consent
heterosexual 47 59 3252 3264 I-contraception_consent
contact 60 67 3265 3272 I-contraception_consent
or 68 70 3273 3275 I-contraception_consent
begin 71 76 3276 3281 I-contraception_consent
TWO 77 80 3282 3285 I-contraception_consent
acceptable 81 91 3286 3296 I-contraception_consent
methods 92 99 3297 3304 I-contraception_consent
of 100 102 3305 3307 I-contraception_consent
birth 103 108 3308 3313 I-contraception_consent
control 109 116 3314 3321 I-contraception_consent
, 116 117 3321 3322 O
one 118 121 3323 3326 O
highly 122 128 3327 3333 O
effective 129 138 3334 3343 O
method 139 145 3344 3350 O
and 146 149 3351 3354 O
one 150 153 3355 3358 O
additional 154 164 3359 3369 O
effective 165 174 3370 3379 O
( 175 176 3380 3381 B-contraception_consent
barrier 176 183 3381 3388 I-contraception_consent
) 183 184 3388 3389 I-contraception_consent
method 185 191 3390 3396 I-contraception_consent
, 191 192 3396 3397 O
AT 193 195 3398 3400 O
THE 196 199 3401 3404 O
SAME 200 204 3405 3409 O
TIME 205 209 3410 3414 O
, 209 210 3414 3415 O
before 211 217 3416 3422 O
starting 218 226 3423 3431 O
pomalidomide 227 239 3432 3444 B-treatment

Must 0 4 3445 3449 O
have 5 9 3450 3454 O
a 10 11 3455 3456 O
negative 12 20 3457 3465 B-pregnancy
serum 21 26 3466 3471 I-pregnancy
or 27 29 3472 3474 I-pregnancy
urine 30 35 3475 3480 I-pregnancy
pregnancy 36 45 3481 3490 I-pregnancy
test 46 50 3491 3495 O
with 51 55 3496 3500 O
a 56 57 3501 3502 O
sensitivity 58 69 3503 3514 O
of 70 72 3515 3517 O
at 73 75 3518 3520 O
least 76 81 3521 3526 O
25 82 84 3527 3529 B-lower_bound
mlU 85 88 3530 3533 I-lower_bound
/ 88 89 3533 3534 I-lower_bound
ml 89 91 3534 3536 I-lower_bound
no 92 94 3537 3539 O
more 95 99 3540 3544 O
than 100 104 3545 3549 O
14 105 107 3550 3552 B-upper_bound
days 108 112 3553 3557 I-upper_bound
prior 113 118 3558 3563 I-upper_bound
to 119 121 3564 3566 O
registration 122 134 3567 3579 O
and 135 138 3580 3583 O
must 139 143 3584 3588 O
agree 144 149 3589 3594 O
to 150 152 3595 3597 O
repeat 153 159 3598 3604 O
this 160 164 3605 3609 O
test 165 169 3610 3614 O
within 170 176 3615 3621 O
24 177 179 3622 3624 B-upper_bound
hours 180 185 3625 3630 I-upper_bound
of 186 188 3631 3633 O
starting 189 197 3634 3642 O
pomalidomide 198 210 3643 3655 B-treatment

Must 0 4 3656 3660 O
have 5 9 3661 3665 O
a 10 11 3666 3667 O
negative 12 20 3668 3676 O
serum 21 26 3677 3682 O
or 27 29 3683 3685 O
urine 30 35 3686 3691 O
pregnancy 36 45 3692 3701 B-clinical_variable
test 46 50 3702 3706 I-clinical_variable
within 51 57 3707 3713 O
72 58 60 3714 3716 B-upper_bound
hours 61 66 3717 3722 I-upper_bound
prior 67 72 3723 3728 I-upper_bound
to 73 75 3729 3731 O
re 76 78 3732 3734 O
- 78 79 3734 3735 O
registration 79 91 3735 3747 O

No 0 2 3748 3750 O
EKG 3 6 3751 3754 B-treatment
evidence 7 15 3755 3763 O
of 16 18 3764 3766 O
> 19 20 3767 3768 O
grade 21 26 3769 3774 B-lower_bound
2 27 28 3775 3776 I-lower_bound
( 29 30 3777 3778 O
> 30 31 3778 3779 O
480 32 35 3780 3783 B-lower_bound
ms 36 38 3784 3786 I-lower_bound
) 38 39 3786 3787 O
corrected 40 49 3788 3797 O
QT 50 52 3798 3800 B-clinical_variable
( 53 54 3801 3802 I-clinical_variable
QTc 54 57 3802 3805 I-clinical_variable
) 57 58 3805 3806 I-clinical_variable
prolongation 59 71 3807 3819 O

No 0 2 3820 3822 O
G 3 4 3823 3824 B-treatment
- 4 5 3824 3825 I-treatment
CSF 5 8 3825 3828 I-treatment
( 9 10 3829 3830 I-treatment
filgrastim 10 20 3830 3840 I-treatment
) 20 21 3840 3841 I-treatment
or 22 24 3842 3844 O
GM 25 27 3845 3847 B-treatment
- 27 28 3847 3848 I-treatment
CSF 28 31 3848 3851 I-treatment
( 32 33 3852 3853 I-treatment
sargramostim 33 45 3853 3865 I-treatment
) 45 46 3865 3866 I-treatment
within 47 53 3867 3873 O
7 54 55 3874 3875 B-upper_bound
days 56 60 3876 3880 I-upper_bound
of 61 63 3881 3883 O
registration 64 76 3884 3896 O
or 77 79 3897 3899 O
pegfilgrastim 80 93 3900 3913 B-treatment
within 94 100 3914 3920 O
14 101 103 3921 3923 B-upper_bound
days 104 108 3924 3928 I-upper_bound
of 109 111 3929 3931 O
registration 112 124 3932 3944 O
to 125 127 3945 3947 O
meet 128 132 3948 3952 O
eligibility 133 144 3953 3964 O
criteria 145 153 3965 3973 O

No 0 2 3974 3976 O
class 3 8 3977 3982 B-lower_bound
3 9 10 3983 3984 I-lower_bound
or 11 13 3985 3987 O
higher 14 20 3988 3994 O
New 21 24 3995 3998 B-clinical_variable
York 25 29 3999 4003 I-clinical_variable
Heart 30 35 4004 4009 I-clinical_variable
Association 36 47 4010 4021 I-clinical_variable
congestive 48 58 4022 4032 I-clinical_variable
heart 59 64 4033 4038 I-clinical_variable
failure 65 72 4039 4046 I-clinical_variable

No 0 2 4047 4049 O
clinically 3 13 4050 4060 O
significant 14 25 4061 4072 O
pericardial 26 37 4073 4084 B-chronic_disease
disease 38 45 4085 4092 I-chronic_disease

No 0 2 4093 4095 O
electrocardiogram 3 20 4096 4113 B-treatment
( 21 22 4114 4115 I-treatment
EKG 22 25 4115 4118 I-treatment
) 25 26 4118 4119 I-treatment
evidence 27 35 4120 4128 O
of 36 38 4129 4131 O
acute 39 44 4132 4137 O
ischemia 45 53 4138 4146 B-chronic_disease

No 0 2 4147 4149 O
history 3 10 4150 4157 O
of 11 13 4158 4160 O
acquired 14 22 4161 4169 B-chronic_disease
immunodeficiency 23 39 4170 4186 I-chronic_disease
syndrome 40 48 4187 4195 I-chronic_disease
( 49 50 4196 4197 I-chronic_disease
AIDS)-defining 50 64 4197 4211 I-chronic_disease
conditions 65 75 4212 4222 O
or 76 78 4223 4225 O
other 79 84 4226 4231 O
HIV 85 88 4232 4235 B-chronic_disease
related 89 96 4236 4243 O
illness 97 104 4244 4251 O

No 0 2 4252 4254 O
history 3 10 4255 4262 O
of 11 13 4263 4265 O
myocardial 14 24 4266 4276 B-chronic_disease
infarction 25 35 4277 4287 I-chronic_disease
within 36 42 4288 4294 O
6 43 44 4295 4296 B-upper_bound
months 45 51 4297 4303 I-upper_bound
prior 52 57 4304 4309 I-upper_bound
to 58 60 4310 4312 O
registration 61 73 4313 4325 O

No 0 2 4326 4328 O
investigational 3 18 4329 4344 B-treatment
therapy 19 26 4345 4352 I-treatment
within 27 33 4353 4359 O
14 34 36 4360 4362 B-upper_bound
days 37 41 4363 4367 I-upper_bound
prior 42 47 4368 4373 I-upper_bound
to 48 50 4374 4376 O
registration 51 63 4377 4389 O

No 0 2 4390 4392 O
major 3 8 4393 4398 B-treatment
surgery 9 16 4399 4406 I-treatment
within 17 23 4407 4413 O
28 24 26 4414 4416 B-upper_bound
days 27 31 4417 4421 I-upper_bound
prior 32 37 4422 4427 I-upper_bound
to 38 40 4428 4430 O
registration 41 53 4431 4443 O

No 0 2 4444 4446 O
other 3 8 4447 4452 O
chemotherapy 9 21 4453 4465 B-treatment
or 22 24 4466 4468 O
radiation 25 34 4469 4478 B-treatment
therapy 35 42 4479 4486 I-treatment
within 43 49 4487 4493 O
14 50 52 4494 4496 B-upper_bound
days 53 57 4497 4501 I-upper_bound
prior 58 63 4502 4507 O
to 64 66 4508 4510 O
registration 67 79 4511 4523 O

No 0 2 4524 4526 O
platelet 3 11 4527 4535 B-treatment
transfusions 12 24 4536 4548 I-treatment
within 25 31 4549 4555 O
7 32 33 4556 4557 B-upper_bound
days 34 38 4558 4562 I-upper_bound
of 39 41 4563 4565 O
registration 42 54 4566 4578 O
to 55 57 4579 4581 O
meet 58 62 4582 4586 O
eligibility 63 74 4587 4598 O
criteria 75 83 4599 4607 O

No 0 2 4608 4610 O
strong 3 9 4611 4617 O
inducers 10 18 4618 4626 O
of 19 21 4627 4629 O
cytochrome 22 32 4630 4640 B-treatment
P450 33 37 4641 4645 I-treatment
( 38 39 4646 4647 I-treatment
CYP 39 42 4647 4650 I-treatment
) 42 43 4650 4651 I-treatment
3A4 44 47 4652 4655 I-treatment
or 48 50 4656 4658 O
CYP1A2 51 57 4659 4665 B-treatment
or 58 60 4666 4668 O
strong 61 67 4669 4675 O
inhibitors 68 78 4676 4686 O
of 79 81 4687 4689 O
CYP3A4 82 88 4690 4696 B-treatment
or 89 91 4697 4699 O
CYP1A2 92 98 4700 4706 O

No 0 2 4707 4709 O
strong 3 9 4710 4716 B-treatment
inducers 10 18 4717 4725 I-treatment
of 19 21 4726 4728 I-treatment
cytochrome 22 32 4729 4739 I-treatment
P450 33 37 4740 4744 I-treatment
( 38 39 4745 4746 I-treatment
CYP 39 42 4746 4749 I-treatment
) 42 43 4749 4750 I-treatment
3A4 44 47 4751 4754 I-treatment
or 48 50 4755 4757 I-treatment
CYP1A2 51 57 4758 4764 I-treatment
or 58 60 4765 4767 O
strong 61 67 4768 4774 B-treatment
inhibitors 68 78 4775 4785 I-treatment
of 79 81 4786 4788 I-treatment
CYP3A4 82 88 4789 4795 I-treatment
or 89 91 4796 4798 I-treatment
CYP1A2 92 98 4799 4805 I-treatment
within 99 105 4806 4812 O
14 106 108 4813 4815 B-upper_bound
days 109 113 4816 4820 I-upper_bound
prior 114 119 4821 4826 I-upper_bound
to 120 122 4827 4829 O
registration 123 135 4830 4842 O

No 0 2 4843 4845 O
uncontrolled 3 15 4846 4858 O
angina 16 22 4859 4865 B-chronic_disease
or 23 25 4866 4868 O
severe 26 32 4869 4875 O
ventricular 33 44 4876 4887 B-chronic_disease
arrhythmias 45 56 4888 4899 I-chronic_disease

Patient 0 7 4900 4907 O
must 8 12 4908 4912 O
have 13 17 4913 4917 O
measurable 18 28 4918 4928 O
disease 29 36 4929 4936 O
or 37 39 4937 4939 O
non 40 43 4940 4943 O
- 43 44 4943 4944 O
measurable 44 54 4944 4954 O
disease 55 62 4955 4962 O
after 63 68 4963 4968 O
progression 69 80 4969 4980 O
on 81 83 4981 4983 O
pomalidomide 84 96 4984 4996 B-treatment
+ 97 98 4997 4998 O
dexamethasone 99 112 4999 5012 B-treatment
, 112 113 5012 5013 O
defined 114 121 5014 5021 O
as 122 124 5022 5024 O
one 125 128 5025 5028 O
or 129 131 5029 5031 O
more 132 136 5032 5036 O
of 137 139 5037 5039 O
the 140 143 5040 5043 O
following 144 153 5044 5053 O
holding 154 161 5054 5061 O
true 162 166 5062 5066 O

Patients 0 8 5067 5075 O
randomized 9 19 5076 5086 O
to 20 22 5087 5089 O
Arm 23 26 5090 5093 O
1 27 28 5094 5095 O
may 29 32 5096 5099 O
opt 33 36 5100 5103 O
to 37 39 5104 5106 O
switch 40 46 5107 5113 O
to 47 49 5114 5116 O
the 50 53 5117 5120 O
3 54 55 5121 5122 B-treatment
- 55 56 5122 5123 I-treatment
drug 56 60 5123 5127 I-treatment
regimen 61 68 5128 5135 I-treatment
following 69 78 5136 5145 O
disease 79 86 5146 5153 O
progression 87 98 5154 5165 O
; 98 99 5165 5166 O
these 100 105 5167 5172 O
patients 106 114 5173 5181 O
must 115 119 5182 5186 O
be 120 122 5187 5189 O
re 123 125 5190 5192 O
- 125 126 5192 5193 O
registered 126 136 5193 5203 O
to 137 139 5204 5206 O
the 140 143 5207 5210 O
study 144 149 5211 5216 O
and 150 153 5217 5220 O
meet 154 158 5221 5225 O
the 159 162 5226 5229 O
eligibility 163 174 5230 5241 O
criteria 175 183 5242 5250 O

Patients 0 8 5251 5259 O
with 9 13 5260 5264 O
human 14 19 5265 5270 B-chronic_disease
immunodeficiency 20 36 5271 5287 I-chronic_disease
virus 37 42 5288 5293 I-chronic_disease
( 43 44 5294 5295 I-chronic_disease
HIV 44 47 5295 5298 I-chronic_disease
) 47 48 5298 5299 I-chronic_disease
infection 49 58 5300 5309 B-chronic_disease
are 59 62 5310 5313 O
eligible 63 71 5314 5322 O

Platelet 0 8 5323 5331 B-clinical_variable
count 9 14 5332 5337 I-clinical_variable
> 15 16 5338 5339 O
= 16 17 5339 5340 O
50 18 20 5341 5343 B-lower_bound
x 21 22 5344 5345 I-lower_bound
10 23 25 5346 5348 I-lower_bound
^ 25 26 5348 5349 I-lower_bound
9 26 27 5349 5350 I-lower_bound
/ 27 28 5350 5351 I-lower_bound
L 28 29 5351 5352 I-lower_bound

Pomalidomide 0 12 5353 5365 B-chronic_disease
naive 13 18 5366 5371 I-chronic_disease
disease 19 26 5372 5379 I-chronic_disease

Previous 0 8 5380 5388 O
hypersensitivity 9 25 5389 5405 O
to 26 28 5406 5408 O
any 29 32 5409 5412 O
of 33 35 5413 5415 O
the 36 39 5416 5419 O
components 40 50 5420 5430 O
of 51 53 5431 5433 O
the 54 57 5434 5437 O
study 58 63 5438 5443 O
treatment 64 73 5444 5453 B-treatment

Primary 0 7 5454 5461 O
or 8 10 5462 5464 O
secondary 11 20 5465 5474 O
plasma 21 27 5475 5481 B-cancer
cell 28 32 5482 5486 I-cancer
leukemia 33 41 5487 5495 I-cancer

Primary 0 7 5496 5503 O
refractory 8 18 5504 5514 O
multiple 19 27 5515 5523 B-cancer
myeloma 28 35 5524 5531 I-cancer
, 35 36 5531 5532 O
where 37 42 5533 5538 O
primary 43 50 5539 5546 O
refractory 51 61 5547 5557 O
multiple 62 70 5558 5566 O
myeloma 71 78 5567 5574 O
is 79 81 5575 5577 O
defined 82 89 5578 5585 O
as 90 92 5586 5588 O
disease 93 100 5589 5596 O
that 101 105 5597 5601 O
is 106 108 5602 5604 O
nonresponsive 109 122 5605 5618 O

Prior 0 5 5619 5624 O
history 6 13 5625 5632 O
of 14 16 5633 5635 O
erythema 17 25 5636 5644 B-chronic_disease
multiforme 26 36 5645 5655 I-chronic_disease
with 37 41 5656 5660 O
thalidomide 42 53 5661 5672 B-treatment
or 54 56 5673 5675 O
lenalidomide 57 69 5676 5688 B-treatment
treatment 70 79 5689 5698 I-treatment

Prior 0 5 5699 5704 O
to 6 8 5705 5707 O
study 9 14 5708 5713 O
entry 15 20 5714 5719 O
, 20 21 5719 5720 O
any 22 25 5721 5724 O
EKG 26 29 5725 5728 B-chronic_disease
abnormality 30 41 5729 5740 I-chronic_disease
at 42 44 5741 5743 O
screening 45 54 5744 5753 O
not 55 58 5754 5757 O
felt 59 63 5758 5762 O
to 64 66 5763 5765 O
put 67 70 5766 5769 O
the 71 74 5770 5773 O
patient 75 82 5774 5781 O
at 83 85 5782 5784 O
risk 86 90 5785 5789 O
has 91 94 5790 5793 O
to 95 97 5794 5796 O
be 98 100 5797 5799 O
documented 101 111 5800 5810 O
by 112 114 5811 5813 O
the 115 118 5814 5817 O
investigator 119 131 5818 5830 O
as 132 134 5831 5833 O
not 135 138 5834 5837 O
medically 139 148 5838 5847 O
significant 149 160 5848 5859 O

Progression 0 11 5860 5871 O
on 12 14 5872 5874 O
lenalidomide 15 27 5875 5887 B-treatment
as 28 30 5888 5890 O
part 31 35 5891 5895 O
of 36 38 5896 5898 O
first 39 44 5899 5904 B-treatment
line 45 49 5905 5909 I-treatment
therapy 50 57 5910 5917 I-treatment
( 58 59 5918 5919 O
lenalidomide 59 71 5919 5931 O
- 71 72 5931 5932 O
refractory 72 82 5932 5942 O
disease 83 90 5943 5950 O
) 90 91 5950 5951 O

Proteasome 0 10 5952 5962 B-treatment
inhibitor 11 20 5963 5972 I-treatment
naive 21 26 5973 5978 O
or 27 29 5979 5981 O
sensitive 30 39 5982 5991 B-chronic_disease
disease 40 47 5992 5999 I-chronic_disease
; 47 48 5999 6000 O

Serum 0 5 6001 6006 B-clinical_variable
M 6 7 6007 6008 I-clinical_variable
- 7 8 6008 6009 I-clinical_variable
protein 8 15 6009 6016 I-clinical_variable
> 16 17 6017 6018 O
= 17 18 6018 6019 O
0.5 19 22 6020 6023 B-lower_bound
g 23 24 6024 6025 I-lower_bound
/ 24 25 6025 6026 I-lower_bound
dL 25 27 6026 6028 I-lower_bound

Serum 0 5 6029 6034 B-clinical_variable
M 6 7 6035 6036 I-clinical_variable
- 7 8 6036 6037 I-clinical_variable
protein 8 15 6037 6044 I-clinical_variable
> 16 17 6045 6046 O
= 17 18 6046 6047 O
1.0 19 22 6048 6051 B-lower_bound
g 23 24 6052 6053 I-lower_bound
/ 24 25 6053 6054 I-lower_bound
dL 25 27 6054 6056 I-lower_bound
( 28 29 6057 6058 O
> 29 30 6058 6059 O
= 30 31 6059 6060 O
0.5 32 35 6061 6064 B-lower_bound
g 36 37 6065 6066 I-lower_bound
/ 37 38 6066 6067 I-lower_bound
dL 38 40 6067 6069 I-lower_bound
for 41 44 6070 6073 O
IgA 45 48 6074 6077 O
or 49 51 6078 6080 O
IgM 52 55 6081 6084 O
myeloma 56 63 6085 6092 O
) 63 64 6092 6093 O

Total 0 5 6094 6099 O
bilirubin 6 15 6100 6109 B-clinical_variable
< 16 17 6110 6111 O
1.5 18 21 6112 6115 B-upper_bound
x 22 23 6116 6117 I-upper_bound
upper 24 29 6118 6123 I-upper_bound
limits 30 36 6124 6130 I-upper_bound
of 37 39 6131 6133 I-upper_bound
normal 40 46 6134 6140 I-upper_bound
( 47 48 6141 6142 I-upper_bound
ULN 48 51 6142 6145 I-upper_bound
) 51 52 6145 6146 I-upper_bound

Treatment 0 9 6147 6156 B-treatment
sensitive 10 19 6157 6166 O
HIV 20 23 6167 6170 B-chronic_disease
and 24 27 6171 6174 O
, 27 28 6174 6175 O
if 29 31 6176 6178 O
on 32 34 6179 6181 O
anti 35 39 6182 6186 B-treatment
- 39 40 6186 6187 I-treatment
HIV 40 43 6187 6190 I-treatment
therapy 44 51 6191 6198 I-treatment
, 51 52 6198 6199 O
HIV 53 56 6200 6203 B-clinical_variable
viral 57 62 6204 6209 I-clinical_variable
load 63 67 6210 6214 I-clinical_variable
< 68 69 6215 6216 O
50 70 72 6217 6219 B-upper_bound
copies 73 79 6220 6226 I-upper_bound
/ 79 80 6226 6227 I-upper_bound
mm^3 80 84 6227 6231 I-upper_bound
within 85 91 6232 6238 O
28 92 94 6239 6241 B-upper_bound
days 95 99 6242 6246 I-upper_bound
prior 100 105 6247 6252 I-upper_bound
to 106 108 6253 6255 O
registration 109 121 6256 6268 O

Urine 0 5 6269 6274 O
M 6 7 6275 6276 O
- 7 8 6276 6277 O
protein 8 15 6277 6284 B-clinical_variable
> 16 17 6285 6286 O
= 17 18 6286 6287 O
200 19 22 6288 6291 B-lower_bound
mg/24 23 28 6292 6297 I-lower_bound
hours 29 34 6298 6303 I-lower_bound

Women 0 5 6304 6309 B-gender
of 6 8 6310 6312 O
childbearing 9 21 6313 6325 O
potential 22 31 6326 6335 O

a 0 1 6336 6337 O
new 2 5 6338 6341 O
line 6 10 6342 6346 O
of 11 13 6347 6349 O
therapy 14 21 6350 6357 B-treatment
also 22 26 6358 6362 O
begins 27 33 6363 6369 O
when 34 38 6370 6374 O
a 39 40 6375 6376 O
planned 41 48 6377 6384 O
treatment 49 58 6385 6394 B-treatment
- 58 59 6394 6395 O
free 59 63 6395 6399 O
interval 64 72 6400 6408 O
is 73 75 6409 6411 O
interrupted 76 87 6412 6423 O
by 88 90 6424 6426 O
the 91 94 6427 6430 O
need 95 99 6431 6435 O
to 100 102 6436 6438 O
start 103 108 6439 6444 O
treatment 109 118 6445 6454 O
due 119 122 6455 6458 O
to 123 125 6459 6461 O
disease 126 133 6462 6469 O
relapse 134 141 6470 6477 O
/ 141 142 6477 6478 O
progression 142 153 6478 6489 O
( 154 155 6490 6491 O
e.g. 155 159 6491 6495 O
a 160 161 6496 6497 O
patient 162 169 6498 6505 O
with 170 174 6506 6510 O
relapsed 175 183 6511 6519 O
myeloma 184 191 6520 6527 B-cancer
achieves 192 200 6528 6536 O
a 201 202 6537 6538 O
partial 203 210 6539 6546 O
response 211 219 6547 6555 O
after 220 225 6556 6561 O
a 226 227 6562 6563 O
planned 228 235 6564 6571 O
8 236 237 6572 6573 O
cycles 238 244 6574 6580 O
of 245 247 6581 6583 O
cyclophosphamide 248 264 6584 6600 B-treatment
, 264 265 6600 6601 O
bortezomib 266 276 6602 6612 B-treatment
and 277 280 6613 6616 O
dexamethasone 281 294 6617 6630 B-treatment
, 294 295 6630 6631 O
enjoys 296 302 6632 6638 O
an 303 305 6639 6641 O
8 306 307 6642 6643 O
- 307 308 6643 6644 O
month 308 313 6644 6649 O
period 314 320 6650 6656 O
off 321 324 6657 6660 O
therapy 325 332 6661 6668 O
but 333 336 6669 6672 O
then 337 341 6673 6677 O
experiences 342 353 6678 6689 O
disease 354 361 6690 6697 O
progression 362 373 6698 6709 O
requiring 374 383 6710 6719 O
re 384 386 6720 6722 O
- 386 387 6722 6723 O
initiation 387 397 6723 6733 O
of 398 400 6734 6736 O
therapy 401 408 6737 6744 O
) 408 409 6744 6745 O

a 0 1 6746 6747 O
new 2 5 6748 6751 O
line 6 10 6752 6756 O
of 11 13 6757 6759 O
therapy 14 21 6760 6767 B-treatment
begins 22 28 6768 6774 O
when 29 33 6775 6779 O
a 34 35 6780 6781 O
planned 36 43 6782 6789 O
therapy 44 51 6790 6797 O
is 52 54 6798 6800 O
modified 55 63 6801 6809 O
to 64 66 6810 6812 O
include 67 74 6813 6820 O
other 75 80 6821 6826 O
treatment 81 90 6827 6836 B-treatment
agents 91 97 6837 6843 I-treatment
( 98 99 6844 6845 O
alone 99 104 6845 6850 O
or 105 107 6851 6853 O
in 108 110 6854 6856 O
combination 111 122 6857 6868 O
) 122 123 6868 6869 O
as 124 126 6870 6872 O
a 127 128 6873 6874 O
result 129 135 6875 6881 O
of 136 138 6882 6884 O
disease 139 146 6885 6892 O
progression 147 158 6893 6904 O
, 158 159 6904 6905 O
disease 160 167 6906 6913 O
relapse 168 175 6914 6921 O
or 176 178 6922 6924 O
treatment 179 188 6925 6934 O
- 188 189 6934 6935 O
related 189 196 6935 6942 O
toxicity 197 205 6943 6951 O
( 206 207 6952 6953 O
e.g. 207 211 6953 6957 O
a 212 213 6958 6959 O
patient 214 221 6960 6967 O
is 222 224 6968 6970 O
progressing 225 236 6971 6982 O
in 237 239 6983 6985 O
the 240 243 6986 6989 O
face 244 248 6990 6994 O
of 249 251 6995 6997 O
lenalidomide 252 264 6998 7010 B-treatment
maintenance 265 276 7011 7022 I-treatment
therapy 277 284 7023 7030 I-treatment
and 285 288 7031 7034 O
has 289 292 7035 7038 O
bortezomib 293 303 7039 7049 B-treatment
and 304 307 7050 7053 O
dexamethasone 308 321 7054 7067 B-treatment
added 322 327 7068 7073 O
into 328 332 7074 7078 O
their 333 338 7079 7084 O
regimen 339 346 7085 7092 O
) 346 347 7092 7093 O

calculated 0 10 7094 7104 O
utilizing 11 20 7105 7114 O
the 21 24 7115 7118 O
Cockcroft 25 34 7119 7128 B-clinical_variable
- 34 35 7128 7129 I-clinical_variable
Gault 35 40 7129 7134 I-clinical_variable
formula 41 48 7135 7142 I-clinical_variable
or 49 51 7143 7145 O
24 52 54 7146 7148 O
- 54 55 7148 7149 O
hour 55 59 7149 7153 O
urine 60 65 7154 7159 O
collection 66 76 7160 7170 O

has 0 3 7171 7174 O
no 4 6 7175 7177 O
evidence 7 15 7178 7186 O
of 16 18 7187 7189 O
active 19 25 7190 7196 O
graft 26 31 7197 7202 B-chronic_disease
versus 32 38 7203 7209 I-chronic_disease
host 39 43 7210 7214 I-chronic_disease
disease 44 51 7215 7222 I-chronic_disease
, 51 52 7222 7223 O
and 53 56 7224 7227 O
no 57 59 7228 7230 O
evidence 60 68 7231 7239 O
of 69 71 7240 7242 O
active 72 78 7243 7249 B-chronic_disease
infection 79 88 7250 7259 I-chronic_disease

has 0 3 7260 7263 O
not 4 7 7264 7267 O
been 8 12 7268 7272 O
naturally 13 22 7273 7282 O
postmenopausal 23 37 7283 7297 O
for 38 41 7298 7301 O
at 42 44 7302 7304 O
least 45 50 7305 7310 O
24 51 53 7311 7313 B-lower_bound
consecutive 54 65 7314 7325 I-lower_bound
months 66 72 7326 7332 I-lower_bound
( 73 74 7333 7334 O
i.e. 74 78 7334 7338 O
, 78 79 7338 7339 O
has 80 83 7340 7343 O
had 84 87 7344 7347 O
menses 88 94 7348 7354 O
at 95 97 7355 7357 O
any 98 101 7358 7361 O
time 102 106 7362 7366 O
in 107 109 7367 7369 O
the 110 113 7370 7373 O
preceding 114 123 7374 7383 B-lower_bound
24 124 126 7384 7386 I-lower_bound
consecutive 127 138 7387 7398 I-lower_bound
months 139 145 7399 7405 I-lower_bound
) 145 146 7405 7406 O

has 0 3 7407 7410 O
not 4 7 7411 7414 O
undergone 8 17 7415 7424 O
a 18 19 7425 7426 O
hysterectomy 20 32 7427 7439 B-treatment
or 33 35 7440 7442 O
bilateral 36 45 7443 7452 B-treatment
oophorectomy 46 58 7453 7465 I-treatment

initial 0 7 7466 7473 O
response 8 16 7474 7482 O
followed 17 25 7483 7491 O
by 26 28 7492 7494 O
progression 29 40 7495 7506 O
on 41 43 7507 7509 O
continuous 44 54 7510 7520 O
lenalidomide 55 67 7521 7533 B-treatment
- 67 68 7533 7534 O
dexamethasone 68 81 7534 7547 B-treatment
+ 82 83 7548 7549 O
/- 83 85 7549 7551 O
elotuzumab 86 96 7552 7562 B-treatment
or 97 99 7563 7565 O
daratumumab 100 111 7566 7577 B-treatment

it 0 2 7578 7580 O
includes 3 11 7581 7589 O
patients 12 20 7590 7598 O
who 21 24 7599 7602 O
never 25 30 7603 7608 O
achieve 31 38 7609 7616 O
MR 39 41 7617 7619 O
or 42 44 7620 7622 O
better 45 51 7623 7629 O
in 52 54 7630 7632 O
whom 55 59 7633 7637 O
there 60 65 7638 7643 O
is 66 68 7644 7646 O
no 69 71 7647 7649 O
significant 72 83 7650 7661 O
change 84 90 7662 7668 O
in 91 93 7669 7671 O
M 94 95 7672 7673 O
- 95 96 7673 7674 O
protein 96 103 7674 7681 O
and 104 107 7682 7685 O
no 108 110 7686 7688 O
evidence 111 119 7689 7697 O
of 120 122 7698 7700 O
clinical 123 131 7701 7709 O
progression 132 143 7710 7721 O
as 144 146 7722 7724 O
well 147 151 7725 7729 O
as 152 154 7730 7732 O
patients 155 163 7733 7741 O
who 164 167 7742 7745 O
meet 168 172 7746 7750 O
criteria 173 181 7751 7759 O
for 182 185 7760 7763 O
true 186 190 7764 7768 O
progressive 191 202 7769 7780 B-chronic_disease
disease 203 210 7781 7788 I-chronic_disease
( 211 212 7789 7790 I-chronic_disease
PD 212 214 7790 7792 I-chronic_disease
) 214 215 7792 7793 I-chronic_disease

ll 0 2 7794 7796 O
participants 3 15 7797 7809 O
must 16 20 7810 7814 O
be 21 23 7815 7817 O
counseled 24 33 7818 7827 O
at 34 36 7828 7830 O
a 37 38 7831 7832 O
minimum 39 46 7833 7840 O
of 47 49 7841 7843 O
every 50 55 7844 7849 O
28 56 58 7850 7852 B-lower_bound
days 59 63 7853 7857 I-lower_bound
about 64 69 7858 7863 O
pregnancy 70 79 7864 7873 B-pregnancy
precautions 80 91 7874 7885 O
and 92 95 7886 7889 O
risks 96 101 7890 7895 O
of 102 104 7896 7898 O
fetal 105 110 7899 7904 O
exposure 111 119 7905 7913 O

patients 0 8 7914 7922 O
with 9 13 7923 7927 O
a 14 15 7928 7929 O
prior 16 21 7930 7935 O
history 22 29 7936 7943 O
of 30 32 7944 7946 O
hepatitis 33 42 7947 7956 B-chronic_disease
C 43 44 7957 7958 I-chronic_disease
that 45 49 7959 7963 O
has 50 53 7964 7967 O
been 54 58 7968 7972 O
successfully 59 71 7973 7985 O
eradicated 72 82 7986 7996 O
with 83 87 7997 8001 O
antiviral 88 97 8002 8011 B-treatment
therapy 98 105 8012 8019 I-treatment
are 106 109 8020 8023 O
eligible 110 118 8024 8032 O

progression 0 11 8033 8044 O
on 12 14 8045 8047 O
lenalidomide 15 27 8048 8060 B-treatment
maintenance 28 39 8061 8072 I-treatment
therapy 40 47 8073 8080 I-treatment
after 48 53 8081 8086 O
initial 54 61 8087 8094 O
induction 62 71 8095 8104 O
+ 72 73 8105 8106 O
/- 73 75 8106 8108 O
consolidation 76 89 8109 8122 O

proteasome 0 10 8123 8133 B-treatment
inhibitor 11 20 8134 8143 I-treatment
sensitive 21 30 8144 8153 O
disease 31 38 8154 8161 O
is 39 41 8162 8164 O
defined 42 49 8165 8172 O
as 50 52 8173 8175 O
a 53 54 8176 8177 O
PR 55 57 8178 8180 O
or 58 60 8181 8183 O
better 61 67 8184 8190 O
to 68 70 8191 8193 O
prior 71 76 8194 8199 B-treatment
proteasome 77 87 8200 8210 I-treatment
inhibitor 88 97 8211 8220 I-treatment
- 97 98 8220 8221 I-treatment
based 98 103 8221 8226 I-treatment
therapy 104 111 8227 8234 I-treatment
that 112 116 8235 8239 O
is 117 119 8240 8242 O
maintained 120 130 8243 8253 O
for 131 134 8254 8257 O
> 135 136 8258 8259 O
= 136 137 8259 8260 O
60 138 140 8261 8263 B-lower_bound
days 141 145 8264 8268 I-lower_bound
from 146 150 8269 8273 O
the 151 154 8274 8277 O
last 155 159 8278 8282 O
dose 160 164 8283 8287 O
of 165 167 8288 8290 O
the 168 171 8291 8294 O
proteasome 172 182 8295 8305 O
inhibitor 183 192 8306 8315 O

red 0 3 8316 8319 B-treatment
blood 4 9 8320 8325 I-treatment
cell 10 14 8326 8330 I-treatment
transfusions 15 27 8331 8343 I-treatment
are 28 31 8344 8347 O
allowed 32 39 8348 8355 O
at 40 42 8356 8358 O
any 43 46 8359 8362 O
time 47 51 8363 8367 O

relapsed 0 8 8368 8376 O
disease 9 16 8377 8384 O
is 17 19 8385 8387 O
myeloma 20 27 8388 8395 B-cancer
that 28 32 8396 8400 O
has 33 36 8401 8404 O
previously 37 47 8405 8415 O
responded 48 57 8416 8425 O
to 58 60 8426 8428 O
prior 61 66 8429 8434 B-treatment
therapy 67 74 8435 8442 I-treatment
( 75 76 8443 8444 O
MR 76 78 8444 8446 B-treatment
or 79 81 8447 8449 O
better 82 88 8450 8456 O
) 88 89 8456 8457 O
and 90 93 8458 8461 O
subsequently 94 106 8462 8474 O
progressed 107 117 8475 8485 O

with 0 4 8486 8490 O
any 5 8 8491 8494 O
therapy 9 16 8495 8502 B-treatment
over 17 21 8503 8507 O
the 22 25 8508 8511 O
course 26 32 8512 8518 O
of 33 35 8519 8521 O
their 36 41 8522 8527 O
disease 42 49 8528 8535 O

